Topping Estimates, Teva Reports $5.1 Billion Q3 Revenue

A day after CEO steps down, company reports 2% increase in sales, with U.S. generics revenues up 6%.

comments Print
A day after its CEO Jeremy Levin was ousted by the board, Teva Pharmaceuticals reported third-quarter earnings on Thursday that were unchanged from a year ago but ahead of analysts' estimates by one cent a...